Targeting Interleukin-1 in Heart Failure and Inflammatory Heart Disease

被引：78
作者：
Van Tassell B.W. [1 ,2 ]
Raleigh J.M.V. [2 ,3 ]
Abbate A. [2 ,3 ]
机构：
[1] Department of Pharmacotherapy and Outcome Sciences, School of Pharmacy, Virginia Commonwealth University, 410 N 12th Street, Room 660, Richmond, 23298-0533, VA
[2] Victoria Johnson Research Laboratories, School of Medicine, Virginia Commonwealth University, Richmond, VA
[3] VCU Pauley Heart Center, School of Medicine, Virginia Commonwealth University, Richmond, VA
来源：
Current Heart Failure Reports | 2015年 / 12卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Acute myocardial infarction; Anakinra; Heart failure; Inflammation; Interleukin-1;
D O I：
10.1007/s11897-014-0231-7
中图分类号：
学科分类号：
摘要：
Heart failure (HF) is a clinical syndrome characterized by dyspnea, fatigue, and poor exercise capacity due to insufficient cardiac function. HF represents the leading cause of hospitalization among adult patients over 65 years of age. Neurohormonal blockade has improved clinical outcomes; however, HF incidence continues to rise, suggesting an urgent need to develop novel drugs that target a different pathophysiological paradigm. Inflammation plays a central role in many cardiovascular diseases. Interleukin-1 (IL-1), a prototypical proinflammatory cytokine, is upregulated in HF and associated with worse prognosis. Preclinical models suggest a beneficial effect of IL-1 blockade, and pilot clinical trials are currently underway to evaluate the role of IL-1 blockade to reduce inflammation, ameliorate ventricular remodeling, and improve exercise capacity in patients with HF. © 2014, Springer Science+Business Media New York.
引用
收藏
页码：33 / 41
页数：8
相关论文
共 59 条
  • [1] Braunwald E., Heart failure, JACC Heart Fail, 1, 1, pp. 1-20, (2013)
  • [2] Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Borden W.B., Et al., Heart disease and stroke statistics-2013 update a report from the American Heart Association, Circulation, 127, pp. E6-E245, (2013)
  • [3] Borlaug B.A., The pathophysiology of heart failure with preserved ejection fraction, Nat Rev Cardiol, 11, 9, pp. 507-515, (2014)
  • [4] Mann D.L., Inflammatory mediators and the failing heart: past, present, and the foreseeable future, Circ Res, 91, 11, pp. 988-998, (2002)
  • [5] Frangogiannis N.G., The inflammatory response in myocardial injury, repair, and remodelling, Nat Rev Cardiol, 11, 5, pp. 255-265, (2014)
  • [6] Dinarello C.A., Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood, 117, pp. 3720-3732, (2011)
  • [7] Testa M., Yeh M., Lee P., Fanelli R., Loperfido F., Berman J.W., Et al., Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension, J Am Coll Cardiol, 28, pp. 964-971, (1996)
  • [8] Mann D.L., Young J.B., Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines, Chest, 105, 3, pp. 897-904, (1994)
  • [9] Anker S.D., von Haehling S., Inflammatory mediators in chronic heart failure: an overview, Heart, 90, 4, pp. 464-470, (2004)
  • [10] Yndestad A., Damas J.K., Oie E., Ueland T., Gullestad L., Aukrust P., Systemic inflammation in heart failure—the whys and wherefores, Heart Fail Rev, 11, 1, pp. 83-92, (2006)
123456